Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q3 2017 call → NOThe question asks whether management describes money or binding financial commitment arriving at the company ahead of the work it will pay for, and whether this advance funding is growing and finances/de-risks the next stage of growth. Looking at the transcript, the key elements are: - Deposits increased $203 million or 12.1% annualized to $6.9 billion - Non-interest bearing accounts make up 28.2% of deposit mix - Interest-bearing public funds decreased - Average cost of interest-bearing deposits at 66 basis points - Municipal deposits generally have high betas - Federal home loan bank borrowings increased by $100 million The question is about whether the company is being paid in front of its own delivery - i.e., customers putting money down, prepayments, deposits that oblige them to pay before receiving something. In banking, deposits are indeed money that customers place with the bank before the bank delivers services. But the question is whether management treats this as advance funding that finances the next stage of growth. Looking at the transcript, Michelle Hickox discusses deposits: "Deposits increased $203 million or 12.1% annualized to $6.9 billion at September 30, 2017, compared to $6.7 billion at June, 30. Non-interest bearing accounts make up 28.2% of the deposit mix at September 30, 2017. In addition, interest-bearing public funds have decreased to 11.1% in 2017 compared to around 17% prior to the Carlile transaction. The average cost of interest-bearing deposits at 66 basis points was up from the second quarter and up 15 basis points from 51 basis points in the third quarter, prior year. While we have still not increased our stated rates on deposit products, municipal deposits generally have high betas, and certain products tied to the Fed Funds rate have increased." This is a bank. Deposits are the raw material of a bank's business - they are how banks fund loans. But the question is whether management describes deposits as "advance funding" that is growing and financing the next stage. The question is quite specific: "the parties on the other side of the company's business are putting cash down, paying earlier, or locking themselves into pay-regardless obligations BEFORE they receive what they are buying" In a bank's case, depositors are putting money into the bank before the bank delivers... what? The bank's product is loans and services.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.